Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report

Alectinib is a selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor as standard therapy for ALK-rearranged non-small cell lung cancer (NSCLC). Hemolytic anemia is considered as a rare but significant adverse event with alectinib. Here, we report a case of a 73-year-old female with lu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	OncoTargets and therapy 2023-01, Vol.16, p.65-69
Hauptverfasser:	Misawa, Kazuhito, Nakamichi, Shinji, Iida, Hiroki, Nagano, Atsuhiro, Mikami, Erika, Tozuka, Takehiro, Matsumoto, Masaru, Miyanaga, Akihiko, Noro, Rintaro, Kubota, Kaoru, Yamaguchi, Hiroki, Seike, Masahiro
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma Anemia Antimitotic agents Antineoplastic agents Blood transfusion Blood transfusions Cancer therapies Care and treatment Case Report Case reports Drug dosages Fusion protein Hemoglobin Hemolytic anemia Laboratories Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Lymphatic system Lymphomas Metastasis Morphology Non-small cell lung carcinoma Patients Protein-tyrosine kinase Small cell lung carcinoma Tomography
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!